[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.

Positive

• Insider increased direct ownership to 63,179 shares through vesting and purchase
• Market purchase of 5,740 shares at $62.65 shows insider added shares with personal funds
• Tax withholding executed by the company was limited to the tax liability (no excess withholding)

Negative

• None.

Insights

Compensation Analyst

Multiple RSU vesting plus a market purchase increases direct insider ownership.

The filing shows 13,550 restricted stock units vesting in three separate awards and a purchase of 5,740 shares at $62.65 on 10/01/2025. Vesting and purchases both increase the reporting person’s direct holdings to 63,179 shares.

The company withheld 5,740 shares to meet tax obligations related to vesting and explicitly states the withheld amount was not in excess of the tax liability.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Freeman Chris

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		1,928	A	$0	51,557	D
Common Stock	10/01/2025		M		1,668	A	$0	53,225	D
Common Stock	10/01/2025		M		9,954	A	$0	63,179	D
Common Stock	10/01/2025		F		5,740(1)	D	$62.65	57,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/01/2025		M			1,928	(2)	(3)	Common Stock	1,928	$0	7,714	D
Restricted Stock Units	$0	10/01/2025		M			1,668	(4)	(3)	Common Stock	1,668	$0	6,669	D
Restricted Stock Units	$0	10/01/2025		M			9,954	(5)	(3)	Common Stock	9,954	$0	20,210	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

5. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vests on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Guardant Health (GH)?

Chris Freeman, Chief Commercial Officer, filed the Form 4 (signed by attorney-in-fact) reporting the transactions.

What transactions did the insider report for GH on 10/01/2025?

The filing reports vesting/crediting of 1,928, 1,668, and 9,954 RSUs and a purchase of 5,740 shares at $62.65.

How many shares does Chris Freeman beneficially own after these transactions?

Following the reported transactions, Mr. Freeman beneficially owned 63,179 shares (direct ownership).

Why were 5,740 shares retained by the company?

The company retained 5,740 shares to satisfy the tax withholding obligations related to the vesting; the filing states the retained amount was not in excess of the tax liability.

What types of equity awards are reported in the Form 4 for GH?

The Form 4 reports Restricted Stock Units (RSUs) vesting and a non-derivative purchase of common stock.